Dr. Jaimie Shores, MD
Claim this profileJohns Hopkins University School of Medicine
Studies Delayed Wound Healing
Studies Hand Injuries
3 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Jaimie Shores, MD is currently running
Hand Transplant
for Hand Loss from Trauma
Background: Millions of people each year sustain injuries, have tumors surgically removed, or are born with defects that require complex reconstructive surgeries to repair. In the case of hand, forearm, or arm amputation, prostheses only provide less than optimal motor function and no sensory feedback. However, hand and arm transplantation is a means to restore the appearance, anatomy, and function of a native hand. Although over 70 hand transplants have been performed to date and good functional results have been achieved, widespread clinical use has been limited due to adverse effects of life-long and high-dose immunosuppression needed to prevent graft rejection. Risks include infection, cancer, and metabolic problems, all of which can greatly affect recipients' quality of life, make the procedure riskier, and jeopardize the potential benefits of hand transplantation. Study Design: This non-randomized, Phase II clinical trial will document the use of a new immunomodulatory protocol (aka - Pittsburgh Protocol, Starzl Protocol) for establishing hand transplantation as a safe and effective reconstructive treatment for upper extremity amputations by minimizing maintenance immunosuppression therapy in unilateral and bilateral hand/forearm transplant patients. This protocol combines lymphocyte depletion with donor bone marrow cell infusion and has enabled graft survival using low doses of a single immunosuppressive drug followed by weaning of treatment. Initially designed for living-related solid organ donation, this regimen has been adapted for use with grafts donated by deceased donors. The investigators propose to perform 30 human hand transplants employing this novel protocol. Specific Aims: 1) To establish hand transplantation as a safe and effective reconstructive strategy for the treatment of upper extremity amputations; 2) To reduce the risk of rejection and enable allograft survival while minimizing the requirement for long-term high dose multi-drug immunosuppression. Significance of Research: Hand transplantation could help upper extremity amputees recover functionality, self-esteem, and the capability to reintegrate into family and social life as "whole" individuals. The protocol offers the potential for minimizing the morbidity of maintenance immunosuppression, thereby beneficially shifting the risk/benefit ratio of this life-enhancing procedure and enabling widespread clinical application of hand transplantation.
Recruiting1 award Phase 2
PEG Fusion
for Peripheral Nerve Injury
The overall objective of this study is to determine the safety of PEG fusion when used with primary repair or reconstruction in patients with an acute upper extremity peripheral nerve injury. PEG is safe and effective for extending the half-life of circulating pharmaceutical products, when used in conjunction with a topical hemostatic agent in surgical wounds, and when used as a colon cleanser for endoscopic surgical procedures. However, PEG fusion has not been rigorously tested as a safe reagent to promote nerve regeneration in humans. Therefore, the goal of this Phase 2a clinical trial is to establish safety data and to examine the effect of PEG fusion on clinical outcomes including recovery of sensory and motor function. Results will be externally validated using data collected in the DoD funded prospective NERVE study and will provide preliminary evidence to power a larger phase II efficacy trial.
Recruiting1 award Phase 24 criteria
More about Jaimie Shores, MD
Clinical Trial Related7 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Jaimie Shores, MD has experience with
- Upper Extremity Allotransplantation
- Deceased Donor Hand Transplantation
- Pittsburgh Protocol
- Single-Drug Immunosuppression
- NTX-001
- PEG Fusion
Breakdown of trials Jaimie Shores, MD has run
Delayed Wound Healing
Hand Injuries
Traumatic Amputation
Wounds and Injuries
Peripheral Nerve Injury
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jaimie Shores, MD specialize in?
Jaimie Shores, MD focuses on Delayed Wound Healing and Hand Injuries. In particular, much of their work with Delayed Wound Healing has involved treating patients, or patients who are undergoing treatment.
Is Jaimie Shores, MD currently recruiting for clinical trials?
Yes, Jaimie Shores, MD is currently recruiting for 2 clinical trials in Baltimore Maryland. If you're interested in participating, you should apply.
Are there any treatments that Jaimie Shores, MD has studied deeply?
Yes, Jaimie Shores, MD has studied treatments such as Upper Extremity Allotransplantation, Deceased Donor Hand Transplantation, Pittsburgh Protocol.
What is the best way to schedule an appointment with Jaimie Shores, MD?
Apply for one of the trials that Jaimie Shores, MD is conducting.
What is the office address of Jaimie Shores, MD?
The office of Jaimie Shores, MD is located at: Johns Hopkins University School of Medicine, Baltimore, Maryland 21287 United States. This is the address for their practice at the Johns Hopkins University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.